Zydus Cadila's ZyCoV-D - the needle-free COVID-19 vaccine for adults and kids - all you need to know
Zydus Cadila in July had said that ZyCoV-D was effective against the new mutants of COVID-19, especially the Delta variant.
ZyCoV-D has shown efficacy rate of 66.6%
Zydus Cadila had applied for the emergency use authorization of ZyCoV-D in July. It was based on an efficacy rate of 66.6% in a late-stage trial of over 28,000 volunteers nationwide. This has been reportedly the largest COVID-19 vaccine trial so far in India.
(Photo: Zydus Cadila)
ZyCoV-D is a three dose coronavirus vaccine
ZyCoV-D is a three dose coronavirus vaccine that will be administered first on day zero, then on day 28th and on the 56th day.
(Photo: Zydus Cadila)
ZyCoV-D is a needle-free COVID-19 vaccine
ZyCoV-D is a needle-free COVID-19 vaccine which is administered using The PharmaJet, a needle-free applicator, which ensures painless intradermal vaccine delivery. This will majorly help in administering the vaccine to kids.
(Photo: IANS)
ZyCoV-D is a Plasmid DNA vaccine
Being a Plasmid DNA vaccine, ZyCoV-D doesn't have any problem associated with vector-based immunity. The Plasmid DNA platform also allows generating new constructs quickly to deal with mutations in the virus.
(Representational Photo: Pixabay)
ZyCoV-D is stored at 2-8 degrees C
ZyCoV-D is stored at 2-8 degrees C and has shown good stability at temperatures of 25 degrees C for at least three months.
(Photo: Zydus Cadila)
Zydus Cadila planning to manufacture 10-12 crore vaccine doses every year
As per Zydus Cadila, the firm is planning to manufacture 10-12 crore vaccine doses of ZyCoV-D annually.
ZyCoV-D is the second home-grown shot
Zydus Cadila's coronavirus vaccine is the second home-grown shot to get emergency authorization in India after Bharat Biotech's Covaxin. It is developed in partnership with the Department of Biotechnology.
ZyCoV-D has also become the sixth COVID-19 vaccine to get approval in India.
(Representational Photo: ANI)
Trending Photos